Antipsychotic [phsu]
Polypharmacy [fndg]
Metabolic [ftcn]
Syndrome [dsyn]
Objective [inpr]
Antipsychotics [phsu]
practice [menp]
Little NOS [cgab, dsyn]
Support [medd]
Safety [hcpp]
Efficacy [qlco]
Increased [qnco]
Metabolic syndrome [dsyn]
Methods [inpr]
newly [idcn]
admitted [hlca]
Adults [aggp]
treated [topp]
Second [qnco]
Generation [tmco]
Antipsychotics [phsu]
assessments [hlca]
Evaluate [ftcn]
Antipsychotic [phsu]
Metabolic syndrome [dsyn]
Triglycerides [bacs, lipd]
High Density Lipoprotein Cholesterol [bacs, lipd]
Ratio [qnco]
3 5 [qnco]
TG [lbpr]
Sensitive [ftcn]
Marker [clna]
Insulin Resistance [patf]
Antipsychotic [phsu]
Associations [menp]
Metabolic syndrome [dsyn]
TG [lbpr]
Comparison [acty]
Multiple [qnco]
logistic [ocac]
Regression Analyses [inpr]
Antipsychotic [phsu]
Present [qnco]
Patients [podg]
Likely [qlco]
Patients [podg]
Schizophrenia [mobd]
treated [topp]
Clozapine [orch, phsu]
quetiapine [orch, phsu]
ziprasidone [orch, phsu]
P NOS [aapp, imft]
Compared [acty]
Antipsychotic [phsu]
Elevated [qlco]
Metabolic syndrome [dsyn]
P NOS [aapp, imft]
TG [lbpr]
P NOS [aapp, imft]
0.016" [qnco]
logistic [ocac]
Regression Analyses [inpr]
Metabolic syndrome [dsyn]
Body Mass Index [diap]
Old age [fndg]
Bipolar Disorder [mobd]
Schizophrenia [mobd]
co-treatment [hlca]
Generation [tmco]
Antipsychotic [phsu]
R- [spco]
P NOS [aapp, imft]
TG [lbpr]
Marker [clna]
Insulin Resistance [patf]
Body Mass Index [diap]
Sex [orgf]
Caucasian Race [popg]
absence [qnco]
aripiprazole [orch, phsu]
treatment [ftcn]
R- [spco]
P NOS [aapp, imft]
Antipsychotic [phsu]
Polypharmacy [fndg]
Dropped [acty]
Models [inpr]
Conclusions [idcn]
Compared [acty]
Patients [podg]
Receive [qlco]
Antipsychotic [phsu]
Patients [podg]
Antipsychotic [phsu]
Metabolic syndrome [dsyn]
Lipid [lipd]
Marker [clna]
Insulin Resistance [patf]
Antipsychotic [phsu]
Abnormalities [cgab]
Known [qlco]
demographic [ocdi]
Anthropometry [resa]
risk factors [qnco]
Published [ocac]
